A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility

• DOI: 10.2147/ijwh.s118687
• Publication Date: 2016-12-07T22:58:28Z
• Authors: Salvatore Gizzo; Juan Antonio Garc...; Franca Heiman; Claudio Ripellino; Klaus Bühler
• Keywords: Biosimilar; Follicle-stimulating hormone receptor; Live birth

Objectives: To perform a cost-effectiveness evaluation comparing the originator follitropin alfa (Gonal-f ® ) to biosimilar (Bemfola in Italian and Spanish contexts, with an assessment of German UK backgrounds. Methods: Starting from study by Rettenbacher et al, model was developed contexts. Clinical data on subjects, doses gonadotropin, pregnancies, live-born children, ovarian hyperstimulation syndrome were used feed model. Costs related drugs, hospitalizations, specialist visits, examinations retrieved tariffs. Gonadotropin acquisition costs for Germany also taken into account expand economical other countries. The done based National Health Service perspective. Sensitivity analyses, both univariate probabilistic, as long scenario tested robustness Results: Originator follicle-stimulating hormone (FSH) €3,663 €6,387 Italy Spain, respectively, whereas FSH €3,483 €6,342. efficacy found be 0.52 0.47 biosimilar. average cost per live birth estimated €7,044 €12,283 €7,411 €13,494 respectively. Furthermore, generated incremental ratio €3,600 €900 Spain compared analyses confirmed results base case Conclusion: This analysis indicated that is cost-efficient treatment strategy health services it would worthwhile extending this Keywords: FSH, alfa, biosimilar, infertility